The latest announcement is out from AIM Vaccine Co., Ltd. Class H ( (HK:6660) ).
AIM Vaccine Co., Ltd. announced that its serum-free iterative rabies vaccine has been accepted for market registration by the National Medical Products Administration, marking a significant technological breakthrough. This vaccine is expected to be the first of its kind globally, enhancing the company’s position in the rabies vaccine market. The vaccine’s development aligns with China’s growing market, projected to reach RMB14.8 billion by 2030, and aims to become the preferred choice for vaccination institutions. The company has completed the necessary infrastructure to produce the vaccine on a large scale, anticipating a substantial boost in its financial results upon regulatory approval and commercialization.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a leading company in the rabies vaccine industry, focusing on the development and production of innovative vaccines. The company is the world’s second-largest supplier of rabies vaccines and is committed to advancing technology in this field. Its primary products include serum-free rabies vaccines, which aim to improve safety and reduce adverse reactions.
YTD Price Performance: -34.85%
Average Trading Volume: 6,163,315
Technical Sentiment Signal: Strong Buy
See more insights into 6660 stock on TipRanks’ Stock Analysis page.